Cenova Capital, established in 2010, is a Shanghai-based venture capital firm specializing in late-stage and growth equity investments in the life sciences and healthcare sectors in China. It focuses on sub-sectors such as pharmaceuticals, medical technology, healthcare services, precision medicine, e-health, and digital health, including artificial intelligence and big data applications. With five funds under management, Cenova has invested in over 50 companies, facilitating the transformation of China's healthcare system. Its investors are primarily large domestic and international institutional investors.
Vivace Therapeutics, Inc. is a drug discovery and development company focused on creating cancer therapies that target the Hippo pathway, which plays a crucial role in tissue regeneration and organ development. Established in 2014 and located in the San Francisco Bay Area, Vivace Therapeutics employs an innovative approach to develop small molecule treatments aimed at improving patient outcomes in oncology. The company collaborates with leading academic institutions to advance research and develop therapies that can be used alone or in combination with existing treatments. With a commitment to enhancing cancer care, Vivace Therapeutics is dedicated to delivering novel solutions that can help patients combat cancer more effectively.
Weimai
Series D in 2025
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.
Haofeng Medtech
Series B in 2025
Haofeng Medtech is a contract development and manufacturing organization (CDMO) that specializes in interventional medical devices. The company offers a range of services tailored to the needs of developers in this sector, focusing on the design, development, and production of these innovative medical technologies. To better serve its clients, Haofeng Medtech has established various wholly-owned subsidiaries, allowing it to address specific requirements within the CDMO industry chain. By enhancing the efficiency of treatment solutions, the company aims to support its clients in advancing healthcare outcomes.
Agile Medical
Series A in 2024
Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software.
JLand Biotech
Series B in 2023
Jiangsu Jland Biotech specializes in the development and production of Biollagen™, a non-animal-sourced collagen. The company is committed to becoming the largest supplier of this type of collagen globally. Utilizing advanced bioengineering technologies, including genetic recombination, microbial fermentation, and protein separation and purification, Jland Biotech designs and manufactures recombinant collagen. Their products cater to various industries, notably cosmetics and food, emphasizing the importance of sustainable and ethical sourcing in the collagen market.
Phage Pharm
Series B in 2023
PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.
Eluminex Biosciences
Series B in 2023
Eluminex Biosciences is focused on researching and commercializing innovative therapies aimed at addressing unmet medical needs in ocular health. Specializing in ophthalmology and tissue regeneration, the company develops solutions based on recombinant human collagen. Its product pipeline is designed to mitigate the effects of aging and overuse on vision, thereby enhancing treatment options for healthcare providers and improving patient outcomes in the diagnosis and management of ocular conditions.
Pulnovo Medical
Venture Round in 2022
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
BestCovered
Series A in 2022
BestCovered is a company focused on developing digital screening tools aimed at early detection and intervention for Alzheimer's disease. By leveraging artificial intelligence technologies, including speech analysis, gesture recognition, and natural language processing, BestCovered creates cognitive impairment risk assessment tools. These tools enable hospitals to achieve high prediction accuracy for Alzheimer's, facilitating timely care for patients. Additionally, BestCovered offers systematic multi-dimensional activation courses designed to help individuals maintain a flexible mind, further contributing to cognitive health and well-being.
Hunan Yiyi Pharmaceutical Technology
Series B in 2022
Hunan Yiyi Pharmaceutical Technology develops and operates an online platform for pharmaceutical products. It allows members to purchase various medicines. Hunan Yiyi Pharmaceutical Technology was founded in 2019 and is based in Jiangsu, China.
Huili Bio
Series A in 2022
Huili Bio is a next-generation synthetic biology enzyme computational design platform.
Yuanyin Bio
Series A in 2022
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.
Zhongze Therapeutics
Seed Round in 2022
Zhongze Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for psychiatric and neurological disorders. The company aims to address unmet medical needs in the central nervous system (CNS) by creating transformative drug candidates that provide effective treatment options for patients suffering from these conditions. Through its focused research and development efforts, Zhongze Therapeutics seeks to advance new therapies that can significantly improve patient outcomes in the realm of CNS diseases.
ENSEM Therapeutics
Series A in 2022
ENSEM Therapeutics is an innovative drug discovery and development company focused on creating precision medicines for oncology. Utilizing its Kinetic Ensemble platform, the company aims to discover and develop transformative small-molecule therapies that address complex drug targets associated with cancer. By integrating advanced technologies, ENSEM Therapeutics can detect and characterize rare conformational states in drug targets, which are crucial for understanding oncogenic processes, regulatory mechanisms, and drug resistance. This approach opens new avenues for therapeutic intervention, allowing drug developers to target high-value and challenging areas within oncology while also considering potential applications in genetic disorders and other diseases.
Jiandanxinli (aka Simple Psychology)
Series B in 2022
Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.
TreeENT
Series A in 2022
TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.
AnHeart Therapeutics
Series B in 2021
AnHeart Therapeutics is a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of innovative pharmaceutical products. The company focuses on acquiring, developing, and commercializing novel therapies that enhance human health and quality of life. Its primary research product, AB-106, is an oral, highly selective small molecule inhibitor targeting ROS1 and NTRK, aimed at providing effective treatment options for cancer. By advancing its pipeline of precision therapies, AnHeart Therapeutics seeks to enable medical professionals to deliver significant medical advancements in oncology.
UP Clinic
Series B in 2021
UP Clinic is a specialized orthopedic rehabilitation center focused on diagnosing and treating sports medicine, musculoskeletal rehabilitation, and orthopedic-related conditions. The clinic caters to sports enthusiasts, orthopedic patients, and individuals recovering from surgery, offering a comprehensive range of patient-centered medical services. With a team of professional medical experts and advanced equipment, UP Clinic emphasizes evidence-based medicine to ensure effective treatments. The facility aims to provide a one-stop solution for patients seeking rehabilitation and orthopedic care, promoting recovery and overall health through specialized services.
Yuanyin Bio
Seed Round in 2021
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.
Umai Technology
Series A in 2021
Umai Technology is a skin image management software firm providing image processing, information acquisition, and clinical diagnosis.
magAssist
Series C in 2021
Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.
Pulnovo Medical
Venture Round in 2021
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Umai Technology
Series A in 2021
Umai Technology is a skin image management software firm providing image processing, information acquisition, and clinical diagnosis.
VivaVision Biotech
Series D in 2021
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.
Forerunner Medical
Series B in 2021
Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.
Orient Speech Therapy
Series C in 2021
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.
Bang Er Orthopedic
Series D in 2021
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.
Weimai
Series C in 2020
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.
Unionlab
Series A in 2020
Unionlab provides clinical CRO services with a focus on the field of oncology. Unionlab delivers an integrated service from the strategy to implementation, including strategy consultation, medical affairs, clinical study operation, third-party independent imaging review, data management, bioanalysis, FSP, and other related services.
Baikemy.com
Series B in 2019
Baikemy.com is a health encyclopedia based in Beijing, China, focused on delivering authoritative healthcare knowledge to users. The platform serves as a scientific and practical resource for the dissemination and exchange of medical information, offering a range of products including authoritative articles and medical videos. Baikemy.com collaborates with top-tier hospitals to create high-quality knowledge materials, enhancing users' understanding of health care. Its offerings include scientific articles, a mutual aid community, and comprehensive medical information services, all designed to empower individuals with reliable health-related knowledge.
Weimai
Series C in 2019
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.
Phoebus Medical Technology
Series A in 2018
Phoebus Medical Technology is a healthcare company that specializes in developing an AI-driven chronic disease management platform. This platform is designed for professional disease monitoring, with a particular focus on diabetic retinopathy. By utilizing artificial intelligence technology, Phoebus Medical Technology aims to enhance the monitoring and management of chronic diseases, offering innovative solutions to treatment institutions. The company's mission is to provide reliable technological support that improves the quality of care for patients with chronic conditions.
Weimai
Series B in 2018
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.
Sport With Fun
Angel Round in 2018
Sport With Fun is a sports and events photography company that provides photography services for sporting events.
Luqa Pharmaceuticals
Series B in 2018
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company based in Central, Hong Kong, that focuses on the development and commercialization of innovative healthcare products primarily for the Chinese market. Established in 2010, Luqa offers a diverse portfolio that includes dermatological and gastrointestinal products. Its dermatology line features Ebernet, a cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the gastrointestinal and oral care sectors, Luqa provides Lacteol, a probiotic for vulnerable patients, and GelX, a medical device for oral cavity lesions. Additional offerings include GelX Xero for dry mouth relief and Aftacure for treating oral mucosa irritations. The company also markets Ialuxid Gel for post-surgical wounds and Podofilm for benign epithelial formations. Luqa Pharmaceuticals aims to enhance the quality of life for patients by delivering effective solutions to prescribers and healthcare providers across China, Hong Kong, and Macau.
Virtus Medical Holding
Venture Round in 2018
Virtus Medical Holding is a provider of outpatient medical services that integrates a diverse range of healthcare disciplines to offer comprehensive care. The organization focuses on patient-centered care coordination, facilitating services from wellness and prevention to treatment and rehabilitation for individuals at various stages of the health cycle. Virtus combines high-end specialists with state-of-the-art healthcare facilities to deliver essential medical procedures, including physiotherapy, surgery, vaccinations, and rehabilitation services. Its commitment to integrated healthcare is exemplified through the establishment of an integrated medical tower and a custom clinic management system, supported by a team of health consultants dedicated to optimizing patient care.
Vivace Therapeutics
Series B in 2017
Vivace Therapeutics, Inc. is a drug discovery and development company focused on creating cancer therapies that target the Hippo pathway, which plays a crucial role in tissue regeneration and organ development. Established in 2014 and located in the San Francisco Bay Area, Vivace Therapeutics employs an innovative approach to develop small molecule treatments aimed at improving patient outcomes in oncology. The company collaborates with leading academic institutions to advance research and develop therapies that can be used alone or in combination with existing treatments. With a commitment to enhancing cancer care, Vivace Therapeutics is dedicated to delivering novel solutions that can help patients combat cancer more effectively.
LinkDoc
Series B in 2016
LinkDoc Technology Limited, founded in 2014 and headquartered in Beijing, China, specializes in medical data solutions and oncology-focused big data platforms. The company provides structured clinical data to oncology hospitals, aiding them in addressing various scientific and clinical challenges. Additionally, LinkDoc is committed to ensuring patient privacy and data security, adhering to standards set by the US HIPAA Act. The company focuses on delivering continuous care for patients with critical diseases and offers data-driven solutions that support life sciences companies and healthcare professionals in enhancing clinical research and facilitating real-world application of medical advancements.
AoHua
Series C in 2016
Aohua is a global provider of endoscopy devices and solutions, specializing in the research, development, production, and sales of electronic endoscope equipment as well as endoscopic diagnostic and surgical consumables. Founded in 1994 and based in Shanghai, China, Aohua aims to lead in endoscope technology innovation and advance the progress of endoscopic diagnosis and treatment. The company is committed to enhancing medical practices through its advanced technological offerings in the endoscopy field.
ASLAN Pharmaceuticals
Series C in 2015
ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.
Yaoshi Quanyun Jiankang
Angel Round in 2015
Yaoshi Quanyun Jiankang is a cloud platform for claiming health insurance policies.
INNOMED
Series A in 2015
Innomed engages in the development and manufacturing of interventional and implantable medical devices. The company's team has a wide range of skills, including developing and discovering new medical devices, using cutting-edge implantable materials, designing and evaluating products, optimizing manufacturing processes, implementing quality, clinical, and regulatory standards, and managing and developing staff.
Juliye
Series A in 2015
Juliye Care is a healthcare service platform focused on integrating medical supply chains and managing chronic diseases. The company connects medical needs with healthcare resources, serving hundreds of thousands of patients across numerous cities and regions. Through its services, Juliye Care aims to address the practical healthcare requirements of individuals, facilitating better access to necessary medical support and resources.
Etong Health
Series A in 2015
Etong Health specializes in healthcare management services, focusing on providing comprehensive health solutions to large and medium-sized enterprises. The company offers a range of services, including physical examinations, health assessments, and health management, as well as educational and consultation services related to health. Through its online platform, Etong Health enables clients to access third-party health management services, which include file recording, health intervention, and personalized health evaluations. This approach allows enterprises to streamline their health check processes and enhance overall employee well-being.
Etong Healthcare
Series A in 2015
EtongOnline Shanghai Medical Consulting provides third-party health management services to large and medium-sized enterprises in Shanghai, Beijing, Shenzhen, Guangzhou, Wuhan, & Chengdu. Its healthy management services include file recording, health assessment, health intervention, health education, health consultation, and private doctor services. The company also provides health examination services, such as employment health check, physical examination, PET-CT testing, gene detection, and enterprise welfare health check services. In addition, it offers medical services, such as medical guidance, specialist appointment, admission solutions, surgery appointment, secondary consultation, and particular examination arrangement services. Further, the company provides services in the areas of establishment of health infirmary, enterprise stratified health management, overseas medical, medical tourism, liability insurance, and oral care. EtongOnline Shanghai Medical Consulting was founded in 2009 and is headquartered in Shanghai City, China.
IMPACT Therapeutics
Series A in 2014
IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.
ASLAN Pharmaceuticals
Series B in 2013
ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.
fUGAO
Series B in 2013
fUGAO is a medical information system solutions provider company.
AoHua
Series A in 2013
Aohua is a global provider of endoscopy devices and solutions, specializing in the research, development, production, and sales of electronic endoscope equipment as well as endoscopic diagnostic and surgical consumables. Founded in 1994 and based in Shanghai, China, Aohua aims to lead in endoscope technology innovation and advance the progress of endoscopic diagnosis and treatment. The company is committed to enhancing medical practices through its advanced technological offerings in the endoscopy field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.